Literature DB >> 29620236

Critical role for non‑GAP function of Gαs in RGS1‑mediated promotion of melanoma progression through AKT and ERK phosphorylation.

Meng-Yan Sun1, Yuchong Wang2, Ji Zhu2, Chuan Lv2, Kai Wu2, Xin-Wei Wang2, Chun-Yu Xue2.   

Abstract

Regulator of G‑protein signaling 1 (RGS1) has been found to be a critical factor in melanoma and other malignancies. However, the mechanism involved in the RGS1‑mediated promotion of melanoma progression is not clear. We based our study on samples collected from pathological specimens of melanoma patients. We found by immunohistochemistry that RGS1 expression was significantly higher in melanoma than that noted in nevus tissue (P<0.05). Kaplan‑Meier analysis demonstrated a significant correlation between increased RGS1 expression and reduced disease‑specific survival (P<0.05). RGS1 expression was also found to be related to the proliferation and migration of melanoma cells. RGS1 was able to bind to the Gαs in immunoprecipitation, but this interaction did not accelerate GTP hydrolysis in our experiment. Furthermore, we found that RGS1 may promote melanoma progression through the downstream effects of Gαs signaling, such as the increased phosphorylation of AKT and ERK by western blotting. Our results demonstrated that RGS1 promotes melanoma progression through regulation of Gαs‑mediated inactivation of AKT and ERK. Therefore, RGS1 is a novel therapeutic target for melanoma treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620236     DOI: 10.3892/or.2018.6341

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Regulator of G-protein signaling 1 promotes choroidal neovascularization in age-related macular degeneration.

Authors:  Qi Zhang; Fengbin Zhang; Yangchen Guo; Yanyan Liu; Ningxin Pan; Hong Chen; Ju Huang; Bifan Yu; Aimin Sang
Journal:  Ann Transl Med       Date:  2022-09

2.  MicroRNA-376b-3p targets RGS1 mRNA to inhibit proliferation, metastasis, and apoptosis in osteosarcoma.

Authors:  Lei Zhang; Meng Yao; Weikang Ma; Yongqing Jiang; Wenbo Wang
Journal:  Ann Transl Med       Date:  2021-11

3.  RGS1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation.

Authors:  Siyang Zhang; Han Wang; Jiao Liu; Tao Tao; Zhi Zeng; Min Wang
Journal:  J Transl Med       Date:  2022-07-25       Impact factor: 8.440

4.  Transcriptomic profile of adverse neurodevelopmental outcomes after neonatal encephalopathy.

Authors:  Myrsini Kaforou; Jethro Herberg; Sudhin Thayyil; Paolo Montaldo; Aubrey Cunnington; Vania Oliveira; Ravi Swamy; Prathik Bandya; Stuti Pant; Peter J Lally; Phoebe Ivain; Josephine Mendoza; Gaurav Atreja; Vadakepat Padmesh; Mythili Baburaj; Monica Sebastian; Indiramma Yasashwi; Chinnathambi Kamalarathnam; Rema Chandramohan; Sundaram Mangalabharathi; Kumutha Kumaraswami; Shobha Kumar; Naveen Benakappa; Swati Manerkar; Jayashree Mondhkar; Vinayagam Prakash; Mohammed Sajjid; Arasar Seeralar; Ismat Jahan; Sadeka Choudhury Moni; Mohammod Shahidullah; Radhika Sujatha; Manigandan Chandrasekaran; Siddarth Ramji; Seetha Shankaran
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

5.  OSskcm: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles.

Authors:  Lu Zhang; Qiang Wang; Lijie Wang; Longxiang Xie; Yang An; Guosen Zhang; Wan Zhu; Yongqiang Li; Zhihui Liu; Xiaochen Zhang; Panpan Tang; Xiaozheng Huo; Xiangqian Guo
Journal:  Cancer Cell Int       Date:  2020-05-19       Impact factor: 5.722

6.  The landscape of host genetic factors involved in immune response to common viral infections.

Authors:  Linda Kachuri; Stephen S Francis; Maike L Morrison; George A Wendt; Yohan Bossé; Taylor B Cavazos; Sara R Rashkin; Elad Ziv; John S Witte
Journal:  Genome Med       Date:  2020-10-27       Impact factor: 15.266

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.